LTR Pharma Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	1.51	0.05	-	-	-
Other Revenue	-	-	-	0.01	-
Revenue	1.51	0.05	-	0.01	-
Revenue Growth (YoY)	2978.25%	-	-	-	-
Cost of Revenue	2.79	3.51	-	-	-
Gross Profit	-1.28	-3.46	-	0.01	-
Selling, General & Admin	3.63	2.01	0.59	0.68	0.03
Research & Development	-	-	0.82	0.35	-
Other Operating Expenses	0.4	0.17	0.03	-	-
Operating Expenses	4.83	3.48	1.44	1.03	0.03
Operating Income	-6.11	-6.94	-1.44	-1.02	-0.03
Interest Expense	-0	-0	-0	-0	-0.01
Interest & Investment Income	0.6	0	0	0	0
Earnings From Equity Investments	-0.06	-	-	-	-
Currency Exchange Gain (Loss)	-0.02	-0.01	-0.02	-0.01	-0
Pretax Income	-5.59	-6.95	-1.45	-1.03	-0.04
Net Income	-5.59	-6.95	-1.45	-1.03	-0.04
Net Income to Common	-5.59	-6.95	-1.45	-1.03	-0.04
Shares Outstanding (Basic)	167	139	260	-	-
Shares Outstanding (Diluted)	167	139	260	-	-
Shares Change (YoY)	19.96%	-46.34%	-	-	-
EPS (Basic)	-0.03	-0.05	-0.01	-	-
EPS (Diluted)	-0.03	-0.05	-0.01	-	-
Free Cash Flow	-4.45	-5.09	-1.54	-0.57	-0.03
Free Cash Flow Per Share	-0.03	-0.04	-0.01	-	-
Gross Margin	-84.75%	-	-	100.00%	-
Operating Margin	-404.86%	-14162.27%	-	-11195.03%	-
Profit Margin	-370.83%	-14192.25%	-	-11314.40%	-
Free Cash Flow Margin	-294.96%	-10396.58%	-	-6258.86%	-
EBITDA	-6.1	-6.94	-	-	-
D&A For EBITDA	0	0	-	-	-
EBIT	-6.11	-6.94	-1.44	-1.02	-0.03
Revenue as Reported	2.1	0.05	-	-	-
Advertising Expenses	0.75	0.36	-	0	0.01

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.